Tenderwize
Retour à la recherche

Conclusion of non-exclusive drug rebate agreement according to § 130a para. 8 SGB V via an open-house model for pharmaceuticals with the trade name Orylmyte (ATC V01AA03)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Aug 31, 2028 · 741 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No guaranteed minimum purchase quantities; actual demand depends on prescription and dispensing behavior, making revenu...

The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, typically 8-12 mon...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Aug 2028
  • Conclusion of non-exclusive rebate agreement for Orylmyte (ATC V01AA03) under § 130a(8) SGB V
  • Supply of Orylmyte and parallel/reimports subject to rebate agreement
Afficher le résumé complet

Non-exclusive rebate agreement for the pharmaceutical product Orylmyte (ATC V01AA03) under an open-house model with AOK PLUS. The agreement is open to all interested pharmaceutical entrepreneurs meeting conditions. No guaranteed volume, no exclusivity. The contract runs until 31 August 2028. First submission deadline 5 August 2026, with ongoing periodic deadlines.

Risques

No guaranteed minimum purchase quantities; actual demand depends on prescription and dispensing behavior, making revenu...

The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, typically 8-12 mon...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG
  • Must comply with EU Russia sanctions regulation (Art. 5k of Regulation 833/2014)

Eligibility

  • Must not have exclusion grounds per §§123,124 GWB

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Conclusion of non-exclusive drug rebate agreement according to § 130a para. 8 SGB V via an open-house model for pharmaceuticals with the trade name Orylmyte (ATC V01AA03)

Non-exclusive rebate agreement for Orylmyte, open to all qualified pharmaceutical entrepreneurs, no guaranteed minimum quantities, performance in Dresden, Saxony/Thuringia.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Aug 2026 - Aug 2028

Catégorie

Pharmaceutical products

Date limite

Expired Aug 05, 2026

Détails de la procédure

Date de publication
09 Jul 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
477816-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026

Aug 21

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31